Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.
Kassem
Sameer A
SA
Diabetes Unit, Department of Internal Medicine, Hadassah Medical Center, Jerusalem, Israel. sameerkassem@gmail.com
Raz
Itamar
I
D000284:Administration, Oral; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D003925:Diabetic Angiopathies / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005907:Gliclazide / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D009017:Morbidity; D011237:Predictive Value of Tests; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D008687:Metformin; D005907:Gliclazide